In pursuit of our objective to shape healthcare policy through the creation and dissemination of credible, relevant research and insights, we have partnered with these organizations:
Brigham and Women’s Hospital
PPI is funding new research and data modeling on the impact of interclass competition on drug prices. The work assesses market conditions and other mechanisms needed for prices to fall among existing drugs in a class when new, brand-name competitor drugs are approved in the same class. A literature review from this work was published in PLOS Medicine (view report).
Harvard Medical School
PPI is a sponsor of the Healthcare Markets and Regulation (HMR) Lab of the Department of Health Care Policy at Harvard Medical School, and member of the HMR Lab’s Industry Working Group. In addition, PPI is funding research that examines risk selection and the effectiveness of risk mitigation programs in the individual health insurance market.
In partnership with the CareMore Health System, we have sponsored research focused on identifying and characterizing high-cost, high-need patients among the members of a Medicare Advantage plan. Findings from this work were published in the Journal of General Internal Medicine (view the first study and the second study).
Additional research evaluated the impact of Medicare Advantage Special Needs Plan enrollment for individuals with End-Stage Renal Disease. Findings from this work were published in Health Affairs (view study).
Anthem and Eli Lilly and Company have come together to suggest public policy solutions, including:
- Helping spur innovation in tying drug pricing to value, including removing barriers to value-based agreements (view report) and allowing for more robust communication (view report) between health plans and drug makers before a drug is approved;
- Examining the role of risk adjustment in promoting stability in the individual health insurance market by co-sponsoring a roundtable discussion among experts (view report); and
- Exploring the policy and technical considerations associated with changes to the risk adjustment model in the Medicare Advantage program (view report).